Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-07104091 + PF-07220060 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07104091 | PF 07104091|PF07104091 | CDK2 Inhibitor 31 | PF-07104091 inhibits CDK2, which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation (NCI Drug Dictionary). | |
PF-07220060 | PF 07220060|PF07220060 | CDK4 Inhibitor 17 | PF-07220060 inhibits CDK4 and may lead to cell cycle arrest and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05262400 | Phase II | Letrozole + PF-07104091 + PF-07220060 Fulvestrant + PF-07104091 + PF-07220060 PF-07104091 + PF-07220060 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | Active, not recruiting | USA | ESP | CZE | BRA | BGR | ARG | 3 |